Abdurrahman Fatih Aydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abdurrahman Fatih Aydin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Canan Kucukgergin
Istanbul University, Turkey
2 shared publications - Fatma Hande Karpuzoğlu
Department of Medical Biochemistry, Istanbul Faculty of Medicine, Istanbul University, 34093 Çapa, Fatih, Istanbul, Turkey.
2 shared publications - Müjdat Uysal
Department of Medical Biochemistry, Istanbul Faculty of Medicine, Istanbul University, 34093 Çapa, Fatih, Istanbul, Turkey
2 shared publications - Semra Doğru-Abbasoğlu
Istanbul Faculty of Medicine
2 shared publications - Ahmed Serkan Emekli
Istanbul University
1 shared publication - Asiye Işın Doğan Ekici
Department of Pathology, School of Medicine, Yeditepe University, Istanbul, Turkey
1 shared publication
Latest Publications
- 15 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Histidine, carnosine, and ergothioneine attenuate pyrazole/LPS-induced hepatotoxicity through modulation of CYP2E1, Nrf2, and NF-κB signaling in mice.
Cytochrome P450 2E1 (CYP2E1) is key in liver damage from oxidative stress. The pyrazole (Pyr)- and lipopolysaccharide (LPS)- induced mouse model, which combines CYP2E1 induction with endotoxemia, is useful for studying liver protection. This study assessed how imidazole compounds (histidine, carnosine, and ergothioneine) affect Pyr + LPS-induced liver injury and the mechanisms involved. Male C57BL/6J mice received histidine (250 mg/kg, i.p.), carnosine (250 mg/kg, i.p.), histidine + carnosine (250 mg/kg each, i.p.), or ergothioneine (70 mg/kg, oral) for 10 consecutive days. Pyrazole (150 mg/kg, i.p.) was administered on days 8 and 9, followed by LPS (10 mg/kg, i.p.) on day 10. Serum ALT and AST activities, hepatic oxidative stress markers (ROS, TBARS, AOPP), antioxidant parameters (GSH, SOD, GSH-Px, FRAP), CYP2E1 protein levels, nitric oxide metabolites (NOx), and mRNA expressions of Nrf2, HO-1, NF-κB, TNF-α, and IL-6 were determined. Histopathological examination was also performed. Pyr + LPS administration significantly elevated serum ALT and AST levels, hepatic CYP2E1, oxidative stress markers, and NOx, while reducing antioxidant defenses. NF-κB, TNF-α, IL-6, and HO-1 mRNA expressions were elevated. Pre-treatment with all imidazole compounds significantly attenuated these alterations, reduced CYP2E1 levels, and further upregulated HO-1 expression. The combination of histidine and carnosine also increased Nrf2 mRNA expression. Histopathological findings corroborated the biochemical results. Histidine, carnosine, and ergothioneine protected against Pyr + LPS-induced hepatic injury and reduced oxidative stress. These effects were accompanied by alterations in CYP2E1 protein levels and NF-κB/Nrf2/HO-1-related gene expression; however, further studies are needed to clarify the underlying mechanisms.
- 15 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Histidine, carnosine, and ergothioneine attenuate pyrazole/LPS-induced hepatotoxicity through modulation of CYP2E1, Nrf2, and NF-κB signaling in mice.
Cytochrome P450 2E1 (CYP2E1) is key in liver damage from oxidative stress. The pyrazole (Pyr)- and lipopolysaccharide (LPS)- induced mouse model, which combines CYP2E1 induction with endotoxemia, is useful for studying liver protection. This study assessed how imidazole compounds (histidine, carnosine, and ergothioneine) affect Pyr + LPS-induced liver injury and the mechanisms involved. Male C57BL/6J mice received histidine (250 mg/kg, i.p.), carnosine (250 mg/kg, i.p.), histidine + carnosine (250 mg/kg each, i.p.), or ergothioneine (70 mg/kg, oral) for 10 consecutive days. Pyrazole (150 mg/kg, i.p.) was administered on days 8 and 9, followed by LPS (10 mg/kg, i.p.) on day 10. Serum ALT and AST activities, hepatic oxidative stress markers (ROS, TBARS, AOPP), antioxidant parameters (GSH, SOD, GSH-Px, FRAP), CYP2E1 protein levels, nitric oxide metabolites (NOx), and mRNA expressions of Nrf2, HO-1, NF-κB, TNF-α, and IL-6 were determined. Histopathological examination was also performed. Pyr + LPS administration significantly elevated serum ALT and AST levels, hepatic CYP2E1, oxidative stress markers, and NOx, while reducing antioxidant defenses. NF-κB, TNF-α, IL-6, and HO-1 mRNA expressions were elevated. Pre-treatment with all imidazole compounds significantly attenuated these alterations, reduced CYP2E1 levels, and further upregulated HO-1 expression. The combination of histidine and carnosine also increased Nrf2 mRNA expression. Histopathological findings corroborated the biochemical results. Histidine, carnosine, and ergothioneine protected against Pyr + LPS-induced hepatic injury and reduced oxidative stress. These effects were accompanied by alterations in CYP2E1 protein levels and NF-κB/Nrf2/HO-1-related gene expression; however, further studies are needed to clarify the underlying mechanisms.
- Open Access
- 19 June 2026
- Published by Elsevier in World Neurosurgery
- Vol. 212, 125143
Ultraviolet-Visible Spectrophotometric Analysis of Intracranial Cyst Fluid: A Technical Note
- 19 June 2026
- Published by Elsevier in World Neurosurgery
- Vol. 212, 125143
Open AccessUltraviolet-Visible Spectrophotometric Analysis of Intracranial Cyst Fluid: A Technical Note
- Open Access
- 11 February 2026
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 53 (2)
Serum lncRNA HOTAIRM1, but not miR-182-5p, as a Potential Non-Invasive Biomarker for Endometrial Cancer
Background: Endometrial cancer (EC) is the second most common gynecological malignancy and remains a major contributor to morbidity and mortality among women worldwide. Current diagnostic and prognostic tools have limited accuracy, highlighting the need for reliable, non-invasive biomarkers. Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), have emerged as promising candidates. This study aimed to investigate serum lncRNA HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) and miR-182-5p expression levels in EC and evaluate their diagnostic value and association with clinicopathological features. Methods: This prospective cohort study analyzed serum samples that were prospectively collected from 73 women with histologically confirmed EC and 76 controls with non-malignant gynecological conditions. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify serum lncRNA HOTAIRM1 and miR-182-5p expression levels. Associations with clinicopathological parameters and diagnostic performance were evaluated. Results: Serum expression levels of lncRNA HOTAIRM1 were significantly higher in EC patients (median [interquartile range (IQR)]: 1.36 [0.74–3.37]) than in controls (1.03 [0.58–2.03]; p = 0.043), whereas miR-182-5p levels showed no significant difference (p = 0.327). Receiver operating characteristic (ROC) curve analysis demonstrated that serum lncRNA HOTAIRM1 had high specificity (93.2%) but low sensitivity (29.6%) for EC diagnosis. No significant associations were identified between either biomarker or clinicopathological variables (p > 0.05). Conclusions: This study provides one of the first evaluations of circulating lncRNA HOTAIRM1 and miR-182-5p in serum samples from patients with EC. Our findings suggest that serum lncRNA HOTAIRM1, but not miR-182-5p, may serve as a potential non-invasive biomarker for EC. Although its limited sensitivity restricts its role as a standalone diagnostic tool, its high specificity supports potential clinical relevance. These preliminary results should be interpreted with caution, as they represent an initial exploratory analysis of circulating lncRNA HOTAIRM1 and miR-182-5p in EC.
- 11 February 2026
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 53 (2)
Open AccessSerum lncRNA HOTAIRM1, but not miR-182-5p, as a Potential Non-Invasive Biomarker for Endometrial Cancer
Background: Endometrial cancer (EC) is the second most common gynecological malignancy and remains a major contributor to morbidity and mortality among women worldwide. Current diagnostic and prognostic tools have limited accuracy, highlighting the need for reliable, non-invasive biomarkers. Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), have emerged as promising candidates. This study aimed to investigate serum lncRNA HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) and miR-182-5p expression levels in EC and evaluate their diagnostic value and association with clinicopathological features. Methods: This prospective cohort study analyzed serum samples that were prospectively collected from 73 women with histologically confirmed EC and 76 controls with non-malignant gynecological conditions. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify serum lncRNA HOTAIRM1 and miR-182-5p expression levels. Associations with clinicopathological parameters and diagnostic performance were evaluated. Results: Serum expression levels of lncRNA HOTAIRM1 were significantly higher in EC patients (median [interquartile range (IQR)]: 1.36 [0.74–3.37]) than in controls (1.03 [0.58–2.03]; p = 0.043), whereas miR-182-5p levels showed no significant difference (p = 0.327). Receiver operating characteristic (ROC) curve analysis demonstrated that serum lncRNA HOTAIRM1 had high specificity (93.2%) but low sensitivity (29.6%) for EC diagnosis. No significant associations were identified between either biomarker or clinicopathological variables (p > 0.05). Conclusions: This study provides one of the first evaluations of circulating lncRNA HOTAIRM1 and miR-182-5p in serum samples from patients with EC. Our findings suggest that serum lncRNA HOTAIRM1, but not miR-182-5p, may serve as a potential non-invasive biomarker for EC. Although its limited sensitivity restricts its role as a standalone diagnostic tool, its high specificity supports potential clinical relevance. These preliminary results should be interpreted with caution, as they represent an initial exploratory analysis of circulating lncRNA HOTAIRM1 and miR-182-5p in EC.
- Open Access
- 28 June 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (3) , 1500-1511
The effect of 1,25-dihydroxyvitamin D3 on liver damage, oxidative stress, and advanced glycation end products in experimental nonalcoholic- and alcoholic- fatty liver disease
Oxidative stress and advanced glycation end products (AGEs) formation are proposed as effective mechanisms in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). 1,25(OH)2D3 was proposed to have antioxidant, antiinflammatory and antiglycation properties. In this study, the effect of 1,25(OH)2 D3 treatment on oxidative stress parameters and AGEs levels together with hepatic histopathology was investigated in high fructose (HFr) or ethanol (EtOH)-treated rats. Rats were treated with fructose (30%) or ethanol (5-20%) in drinking water with and without 1,25(OH)2D3 treatment (5 µg/kg two times a week) for 8 weeks. Insulin resistance (IR), oxidative stress parameters, AGEs, triglyceride (TG) and hydroxyproline (Hyp) levels together with histopathology were investigated in the liver. 1,25(OH)2D3 decreased hepatic reactive oxygen species, lipid and protein oxidation products together with histopathological improvements in HFr- and EtOH-treated rats. 1,25(OH)2D3 treatment was observed to decrease significantly serum and hepatic AGEs in HFr group, and hepatic AGEs in EtOH group. Our results clearly show that 1,25(OH)2 D3 treatment may be useful in the alleviation of hepatic lesions for decreasing glycoxidant stress in both NAFLD and ALD models created by HFr- and EtOH-treated rats, respectively.
- 28 June 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (3) , 1500-1511
Open AccessThe effect of 1,25-dihydroxyvitamin D3 on liver damage, oxidative stress, and advanced glycation end products in experimental nonalcoholic- and alcoholic- fatty liver disease
Oxidative stress and advanced glycation end products (AGEs) formation are proposed as effective mechanisms in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). 1,25(OH)2D3 was proposed to have antioxidant, antiinflammatory and antiglycation properties. In this study, the effect of 1,25(OH)2 D3 treatment on oxidative stress parameters and AGEs levels together with hepatic histopathology was investigated in high fructose (HFr) or ethanol (EtOH)-treated rats. Rats were treated with fructose (30%) or ethanol (5-20%) in drinking water with and without 1,25(OH)2D3 treatment (5 µg/kg two times a week) for 8 weeks. Insulin resistance (IR), oxidative stress parameters, AGEs, triglyceride (TG) and hydroxyproline (Hyp) levels together with histopathology were investigated in the liver. 1,25(OH)2D3 decreased hepatic reactive oxygen species, lipid and protein oxidation products together with histopathological improvements in HFr- and EtOH-treated rats. 1,25(OH)2D3 treatment was observed to decrease significantly serum and hepatic AGEs in HFr group, and hepatic AGEs in EtOH group. Our results clearly show that 1,25(OH)2 D3 treatment may be useful in the alleviation of hepatic lesions for decreasing glycoxidant stress in both NAFLD and ALD models created by HFr- and EtOH-treated rats, respectively.